MedTrace Logo

Determinants in Antidepressant Outcomes

NCT00108316 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-09-27

No results posted yet for this study

Summary

This study is designed to understand if a biological measurement, of how platelets respond to serotonin (a chemical in the blood sometimes referred to as SERT), can provide information that will determine an "ideal dose," one specifically tailored for each individual's chemistry. The biological measurement will be obtained by testing a blood sample. There will be approximately 120 control subjects expected for enrollment.

Conditions

Interventions

DRUG

Fluoxetine (Liquid Prozac)

Sponsors & Collaborators

Principal Investigators

  • Jeffrey Rausch, MD · VA Medical Center, Augusta

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2005-09-30
Completion
2005-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00108316 on ClinicalTrials.gov